Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Samer A. Srour, MB ChB, MS, explains the unique construction of ALLO-316, the potential for ALLO-316 to address an unmet need in patients with clear cell renal cell carcinoma, and how early data from the TRAVERSE study support the continued investigation of ALLO-316 in patients with CD70-expressing tumors.
Plus, New York financier Ron Perelman gave $25 million to Brown University, a Community College got $10 million, and four other universities received multimillion-dollar donations.
Athersys, Inc. , a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy... | April 21, 2023
/cloudfront-us-east-1.images.arcpublishing.com/tgam/6JNMPMNPAVGFTOIWAGCXAY47HI.jpg)
Once unthinkable, the concept of delivering at-home care to stem cell transplant patients is gaining momentum
Samer A. Srour, MB, ChB, MS, discusses the study design of the phase 1 TRAVERSE study, and key data on the use of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.